1. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
- Author
-
Earl, H. M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A-l., Gounaris, I., Abraham, J., Hughes-davies, L., Mcadam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., and ARTemis Investigators Group
- Subjects
Remission Induction ,Breast Neoplasms ,Docetaxel ,Original Articles ,Genes, erbB-2 ,Middle Aged ,bevacizumab ,Survival Analysis ,Neoadjuvant Therapy ,ARTemis ,RC0254 ,Early Diagnosis ,breast cancer ,Antineoplastic Combined Chemotherapy Protocols ,Breast Tumors ,Humans ,Female ,Taxoids ,Fluorouracil ,Cyclophosphamide ,Epirubicin ,neoadjuvant chemotherapy - Abstract
Background The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. Patients and methods Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC), ±4 cycles of Bev (Bev + D-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden (RCB) class. Results A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2–4.4)]. DFS and OS were similar across treatment arms [DFS hazard ratio (HR)=1.18 (95% CI 0.89–1.57), P = 0.25; OS HR = 1.26 (95% CI 0.90–1.76), P = 0.19). Both local pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients who achieved a pCR [DFS HR = 0.38 (95% CI 0.23–0.63), P
- Published
- 2017